SG
GILD icon

Sankala Group’s Gilead Sciences GILD Stock Holding History

Sankala Group’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$348K Sell
2,540
-86
-3% -$12K 0.28% 81
2025
Q4 		$391K Buy
+2,626
New +$319K 0.31% 75

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Sankala Group's GILD Position: Q1 2026 in Review

Sankala Group reduced its Gilead Sciences (GILD) stake by 3.3% in Q1 2026, selling an estimated $12K and leaving 2,540 shares worth $348K. The position accounts for 0.28% of the portfolio, ranked #81.

Sankala Group first reported a position in GILD in Q4 2025 and has held it in 2 quarters since. The position peaked at $391K in Q4 2025. 2,316 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Sankala Group held 2,540 shares of Gilead Sciences worth $348K as of Q1 2026.
  • Sankala Group sold 86 Gilead Sciences shares in Q1 2026, an estimated $12K.
  • Gilead Sciences made up 0.28% of Sankala Group's portfolio in Q1 2026, its #81 holding.
  • Sankala Group first reported a position in Gilead Sciences in Q4 2025 and has held it in 2 quarters since.
  • Sankala Group's Gilead Sciences position peaked at $391K in Q4 2025.
  • 2,316 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Sankala Group's 13F filing for Q1 2026, filed 31 Mar 2026.